Phase 2 Trial of Elranatamab With Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Documentation of Disease: * Patients must have pathologically confirmed diagnosis of multiple myeloma (MM) as defined according to 2014 IMWG criteria. * Measurable disease defined by at least 1 of the following: * Serum M-protein ≥0.5 g/dL by SPEP * Serum immunoglobulin free light chain ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (\<0.26 or \>1.65) * Urinary M-protein excretion ≥200 mg/24 hours by UPEP * Bone marrow plasma cell percentage (in aspirate or biopsy, whichever is higher) of ≥30% * Myeloma bone…
Interventions
- BiologicalElranatamab-bcmm
Elranatamab-bcmm is a recombinant, humanized, bispecific IgG2 kappa antibody
- DrugCyclophosphamide
Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards
Locations (7)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities)Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York